- Safety of everolimus plus exemestane in patients with hormone-recepto…
Number of the records: 1  

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior nonsteroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

  1. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior nonsteroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). / Jerusalem, G. ... [et al.].
    In: Onkológia. -- ISSN 1336-8176. -- Roč. 11, č. 4 (2016), s. 250-251.
    nádory prsníka - farmakoterapia * účinky liekov vedľajšie a nežiaduce reakcie liekov * skúšanie klinické, fáza III, ako téma * kombinácia everolimus a exemestan * bezpečnosť liečby * štúdia BALLET * abstrakt v angličtine
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.